Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 6—June 2014
Research

Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania

Stephen E. Schachterle1, George Mtove, Joshua P. Levens, Emily Clemens, Lirong Shi, Amrita Raj, J. Stephen Dumler, Beatriz Munoz, Shelia West, and David J. SullivanComments to Author 
Author affiliations: Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA (S.E. Schachterle, L. Shi, A. Raj, D.J. Sullivan); National Institute for Medical Research, Ubwari, Tanzania (G. Mtove); Johns Hopkins University School of Medicine, Baltimore (J.P. Levens, E. Clemens, J.S. Dumler, B. Munoz, S. West)

Main Article

Table 4

Resistance markers for cloned sequences of Plasmodium falciparum ribosomal PfRp14 protein gene, Tanzania, January 12–July 21, 2009*

Patient ID Time from azithromycin treatment, d Parasites/μL by light microscopy Parasites/μL by real-time PCR RDT result No. plasmid clones with WT sequence Clones with synonymous SNP (no.) Clones with nonsynonymous SNP (no.) No. plasmids sequenced
1 30 31,200 5,378 + 7 L112L (1) 0 8
2 30 ND 3,177 ND 3 0 0 3
3 30 ND 224.9 ND 0 K36K (4) 0 4
4 67 151,000 126,506 + 2 0 0 2
5 69 74,400 55,850 – 1 S85S (1) 0 2
6 80 49,160 16,410 + 4 0 I38V(1), N109S (1), N166D (1) 7
7 82 1,840 679 + 1 0 F114L (1) 2
8 94 26,760 11,030 – 1 0 T56I (1) 2
9 127 0 51,075 + 3 0 0 3
10 132 ND 22,774 ND 0 0 I39S (1), S65N (1) 4
11 NT 0 69,718 + 13 0 A78S (1),† N134D (1), K100R and I126T (1), N166S (1), Y20H, K100%, and I139T (1) 18
12 NT 11,160 2,495 + 2 0 0 2
Control NT ND 2 0 0 2
Control NT ND 2 0 0 2

*ID, identification; RDT, rapid diagnostic test; WT, wild type; SNP, single-nucleotide polymorphism; +, positive; ND, not done; –, negative; NT, not treated.
†An A78S nonynonymous SNP in region associated with azithromycin resistance that was not present in other clones.

Main Article

1Current affiliation: Pfizer, Inc., New York, New York, USA.

Page created: May 16, 2014
Page updated: May 16, 2014
Page reviewed: May 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external